US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
JP3971797B2
(ja)
*
|
1994-09-23 |
2007-09-05 |
アレクション・ファーマシューティカルズ・インク |
炎症性関節疾患の治療方法
|
KR100425965B1
(ko)
|
1998-02-20 |
2004-04-06 |
타녹스 인코퍼레이티드 |
보체 활성화의 억제물질
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
DE19913707A1
(de)
*
|
1999-03-26 |
2000-10-05 |
Privates Inst Bioserv Gmbh |
Immunadsorber zur Sepsistherapie
|
WO2001002560A1
(en)
*
|
1999-06-29 |
2001-01-11 |
Autogen Research Pty. Ltd. |
Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
|
DE60136272D1
(de)
|
2000-04-29 |
2008-12-04 |
Univ Iowa Res Found |
Diagnostika und therapeutika für makula degeneration erkrankungen
|
WO2002030985A2
(en)
*
|
2000-10-10 |
2002-04-18 |
Tanox, Inc. |
Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
US20020094332A1
(en)
*
|
2001-01-18 |
2002-07-18 |
Alexion Pharmaceuticals |
Method of prophylaxis against large myocardial infractions
|
EP1998266A3
(de)
|
2001-02-19 |
2009-02-11 |
Merck Patent GmbH |
Verfahren zur Identifizierung von T-Zell-Epitopen und Verfahren zur Herstellung von Molekülen mit verminderter Immunogenität
|
US20030109714A1
(en)
*
|
2001-03-22 |
2003-06-12 |
Neil Wishart |
Transition metal mediated process
|
CA2454562A1
(en)
*
|
2001-07-26 |
2003-02-06 |
Alexion Pharmaceuticals, Inc. |
Method of improving cognitive function
|
EP3372243A1
(de)
|
2001-08-17 |
2018-09-12 |
Genentech, Inc. |
Komplement-inhibitoren, die an c5 und c5a binden, ohne die bildung von c5b zu hemmen
|
US7432356B2
(en)
*
|
2001-08-17 |
2008-10-07 |
Genentech, Inc. |
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
|
PT1461428E
(pt)
|
2001-12-03 |
2012-05-29 |
Alexion Pharma Inc |
Método para produção de anticorpos híbridos
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
WO2003081206A2
(en)
*
|
2002-03-18 |
2003-10-02 |
Alexion Pharmaceuticals, Inc. |
Stratification of patient populations having or suspected of having rheumatoid arthritis
|
ITMI20021527A1
(it)
*
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
JP4601426B2
(ja)
|
2002-09-06 |
2010-12-22 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体成分c5に対する抗体を使用する喘息の処置の方法
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
US7361339B2
(en)
*
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
US20090010937A1
(en)
*
|
2004-01-28 |
2009-01-08 |
Chauhan Anil K |
Membrane Attack Complexes Associated with Circulating Immune Complexes
|
US20070116710A1
(en)
*
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
US20090028850A1
(en)
*
|
2004-05-14 |
2009-01-29 |
Alexion Pharmaceuticals, Inc. |
Prolongation of survival of an allograft by inhibiting complement activity
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP1934867A2
(de)
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
|
NZ567483A
(en)
|
2005-11-04 |
2012-04-27 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
US20070196367A1
(en)
*
|
2006-02-22 |
2007-08-23 |
Valentin Dinu |
Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
|
CN101437501B
(zh)
*
|
2006-03-02 |
2012-09-05 |
阿莱克申药物公司 |
通过抑制补体活性延长同种异体移植物的存活
|
MX2008011323A
(es)
|
2006-03-08 |
2008-11-18 |
Archemix Corp |
Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares.
|
SI2359834T1
(sl)
*
|
2006-03-15 |
2017-02-28 |
Alexion Pharmaceuticals, Inc. |
Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
|
JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
EP2013235A1
(de)
*
|
2006-05-01 |
2009-01-14 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung von mit dysferlindefizienz assoziierter muskulärer dystrophie
|
PT2044111E
(pt)
|
2006-06-21 |
2014-11-12 |
Univ Colorado Regents |
Abordagem seletiva do fator h do complemento para o tratamento de doenças
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
AU2007293013B2
(en)
*
|
2006-09-05 |
2013-06-27 |
Alexion Pharmaceuticals, Inc. |
Method and compositions for the treatment of antibody mediated neuropathies
|
PT3028716T
(pt)
*
|
2006-10-10 |
2020-11-23 |
Regenesance B V |
Inibição do complemento para regeneração nervosa melhorada
|
US20090041764A1
(en)
*
|
2006-10-20 |
2009-02-12 |
Alexion Pharmaceuticals, Inc. |
Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
|
EP2907827B1
(de)
|
2006-11-02 |
2018-09-19 |
Genentech, Inc. |
Humanisierte Anti- Faktor-D-Antikörper und Verwendungen davon
|
EP1972639A3
(de)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
|
US20100166748A1
(en)
*
|
2007-03-22 |
2010-07-01 |
Novartis Ag |
C5 Antigens and Uses Thereof
|
US20090068684A1
(en)
*
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2145902A3
(de)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
WO2009023185A1
(en)
*
|
2007-08-13 |
2009-02-19 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
EP3741851A1
(de)
|
2007-10-18 |
2020-11-25 |
Cell Signaling Technology, Inc. |
Translokation und mutante ros-kinase in humanem nichtkleinzelligem lungenkarzinom
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
JP2011516078A
(ja)
|
2008-04-10 |
2011-05-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
癌におけるegfr突然変異を検出する組成物および方法
|
KR20220162801A
(ko)
|
2008-04-11 |
2022-12-08 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
CN102083787A
(zh)
*
|
2008-05-01 |
2011-06-01 |
康普雷克萨公司 |
乙烯基取代的脂肪酸
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
AU2014201433B2
(en)
*
|
2008-08-05 |
2016-05-26 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein C5
|
JP5815403B2
(ja)
*
|
2008-08-05 |
2015-11-17 |
ノバルティス アーゲー |
補体タンパク質c5を標的とする抗体に関する組成物および方法
|
PT2379066E
(pt)
*
|
2008-09-16 |
2014-07-04 |
Imuneks Farma Ilaç Sanayi Ve Ticaret A S |
Uso de antagonistas opioides para a preparação de um medicamento no tratamento das doenças degenerativas da retina
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
BRPI0921237A2
(pt)
|
2008-11-10 |
2015-09-22 |
Alexion Pharma Inc |
métodos e composições para o tratamento de distúrbios associados ao complemento
|
EP2396342B1
(de)
|
2009-02-12 |
2014-09-17 |
Cell Signaling Technology, Inc. |
Expression mutanter ros bei menschlichem leberkrebs
|
PL3903829T3
(pl)
|
2009-02-13 |
2023-08-14 |
Immunomedics, Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
CN102428105B
(zh)
|
2009-02-24 |
2015-09-30 |
阿雷克森制药公司 |
含有治疗性tpo/epo模拟肽的抗体
|
US20100248265A1
(en)
*
|
2009-02-27 |
2010-09-30 |
The Salk Institute For Biological Studies |
Compositions and methods for diagnosis and treatment of cancer
|
CN102597005A
(zh)
*
|
2009-06-23 |
2012-07-18 |
阿雷克森制药公司 |
与补体蛋白质结合的双特异性抗体
|
AU2010266127B2
(en)
|
2009-07-02 |
2015-11-05 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
TR201203732T1
(tr)
*
|
2009-10-01 |
2012-09-21 |
Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. |
Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
|
KR20120130748A
(ko)
|
2009-11-05 |
2012-12-03 |
알렉시온 캠브리지 코포레이션 |
발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료
|
EP2506881B1
(de)
|
2009-12-02 |
2024-03-06 |
Immunomedics, Inc. |
Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie
|
KR20130009784A
(ko)
*
|
2010-03-01 |
2013-01-23 |
알렉시온 파마슈티칼스, 인코포레이티드 |
악성 위축성 구진증을 치료하는 방법 및 조성물
|
TWI667257B
(zh)
*
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
TR201002473A2
(tr)
|
2010-03-31 |
2011-09-21 |
Mustafa Nevzat �La� Sanay�� A.�. |
Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
|
WO2011137362A1
(en)
*
|
2010-04-30 |
2011-11-03 |
Rother Russell P |
Antibodies having reduced immunogenicity in a human
|
US9011852B2
(en)
|
2010-04-30 |
2015-04-21 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies
|
EP2569332B1
(de)
|
2010-05-14 |
2019-01-09 |
The Regents of the University of Colorado, A Body Corporate |
Verbesserte komplement-rezeptor-2-anzielungsgruppen
|
CA2803588A1
(en)
|
2010-06-22 |
2011-12-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the c3d fragment of complement component 3
|
EP2600901B1
(de)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
TW201241008A
(en)
*
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
CN104531671A
(zh)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
设计核酸及其使用方法
|
EP2647706B1
(de)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
|
EP2468295A1
(de)
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Impfstoffe basierend auf Komplementprotein C5a Peptide
|
EP2679681B2
(de)
|
2011-02-25 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIB-spezifischer Fc Antikörper
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
KR101648960B1
(ko)
|
2011-04-15 |
2016-08-22 |
서울대학교산학협력단 |
접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도
|
JP6618682B2
(ja)
|
2011-06-22 |
2019-12-11 |
アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. |
補体阻害剤による慢性障害の治療方法
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
EP3682905B1
(de)
|
2011-10-03 |
2021-12-01 |
ModernaTX, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
US9051365B2
(en)
|
2011-12-21 |
2015-06-09 |
Novartis Ag |
Antibodies that bind factor P
|
DK2817329T3
(en)
|
2012-02-20 |
2019-04-01 |
Swedish Orphan Biovitrum Ab Publ |
Polypeptides Binding to Human Complement Component C5.
|
AU2013243953A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
DK2833907T3
(en)
|
2012-04-06 |
2018-05-28 |
Omeros Corp |
COMPOSITIONS AND METHODS OF INHIBITING MASP-1 AND / OR MASP-3 FOR THE TREATMENT OF PAROXYSTIC NOKTURN HEMOGLOBINURI
|
SI2838998T1
(en)
|
2012-04-18 |
2018-04-30 |
Cell Signaling Technology, Inc. |
EGFR AND ROS1 PRI CRAK
|
CN109908352A
(zh)
|
2012-06-18 |
2019-06-21 |
奥默罗斯公司 |
抑制masp-1和/或masp-2和/或masp-3的组合物和方法
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
BR112015001955A2
(pt)
|
2012-08-24 |
2017-11-07 |
Chugai Pharmaceutical Co Ltd |
variante de região fc específica de fcgamariib
|
TW201418707A
(zh)
*
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
DK2922554T3
(en)
|
2012-11-26 |
2022-05-23 |
Modernatx Inc |
Terminalt modificeret rna
|
BR112015013444B1
(pt)
|
2012-12-13 |
2022-11-01 |
Immunomedics, Inc |
Uso de um imunoconjugado
|
RU2018125515A
(ru)
*
|
2013-01-31 |
2018-10-29 |
СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН |
Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
|
AU2014244116B9
(en)
|
2013-03-14 |
2020-08-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component C5 iRNA compositions and methods of use thereof
|
PE20151893A1
(es)
|
2013-03-14 |
2015-12-30 |
Parkash Gill |
Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3473272A1
(de)
|
2013-03-29 |
2019-04-24 |
Alexion Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur erhöhung der serumhalbwertzeit eines therapeutischen, gegen komplement c5 gerichteten mittels
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc領域改変体
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
CN105683759B
(zh)
|
2013-08-07 |
2019-03-29 |
瑞颂医药公司 |
非典型溶血性尿毒综合征(aHUS)生物标志物蛋白
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
CA2920293A1
(en)
*
|
2013-08-16 |
2015-02-19 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
CN116987154A
(zh)
|
2013-08-28 |
2023-11-03 |
阿菲博迪公司 |
具有突变的支架的结合多肽
|
PT3038633T
(pt)
|
2013-08-28 |
2021-01-14 |
Ipc Res Llc |
Polipéptidos estáveis que se ligam ao complemento humano c5
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
WO2015054569A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
WO2015120130A1
(en)
|
2014-02-07 |
2015-08-13 |
Novartis Ag |
Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
|
CA2939626C
(en)
*
|
2014-02-20 |
2023-01-17 |
Allergan, Inc. |
Complement component c5 antibodies
|
AU2015219495B2
(en)
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
EP3110445A4
(de)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanisierter rfb4-anti-cd22-antikörper
|
KR20160118368A
(ko)
|
2014-02-25 |
2016-10-11 |
아칠리온 파르마세우티칼스 인코포레이티드 |
보체 매개된 장애의 치료를 위한 에터 화합물
|
BR112016019286B1
(pt)
*
|
2014-02-26 |
2024-02-20 |
Allergan, Inc. |
Anticorpo anti-c5
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
MA39934A
(fr)
|
2014-05-01 |
2017-03-08 |
Hoffmann La Roche |
Variants d'anticorps anti-facteur d et leurs utilisations
|
AU2015256299C1
(en)
|
2014-05-05 |
2022-01-06 |
Regeneron Pharmaceuticals, Inc. |
Humanized C5 and C3 animals
|
EP3628680B1
(de)
|
2014-06-12 |
2021-09-08 |
RA Pharmaceuticals, Inc. |
Modulation der komplementaktivität
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
US10568568B2
(en)
|
2014-08-27 |
2020-02-25 |
Capnia, Inc. |
Methods for immune globulin administration
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016061165A1
(en)
|
2014-10-15 |
2016-04-21 |
Alexion Pharmaceuticals, Inc. |
Methods of culturing a cell
|
US9908932B2
(en)
|
2014-10-15 |
2018-03-06 |
Alexion Pharmaceuticals, Inc. |
Methods of shifting an isoelectric profile of a protein product and uses thereof
|
ES2719876T3
(es)
|
2014-10-15 |
2019-07-16 |
Alexion Pharma Inc |
Métodos para replicar un cultivo celular de producción de eculizumab a gran escala
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
KR102515796B1
(ko)
|
2014-12-19 |
2023-03-30 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 그의 사용 방법
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
RS62630B9
(sr)
|
2015-01-28 |
2022-04-29 |
Ra Pharmaceuticals Inc |
Modulatori aktivnosti komplementa
|
WO2016151558A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
TR201904903T4
(tr)
|
2015-03-25 |
2019-05-21 |
Alexion Pharma Inc |
Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
US20180311299A1
(en)
|
2015-05-01 |
2018-11-01 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
US10532087B2
(en)
|
2015-06-03 |
2020-01-14 |
Children's Hospital Medical Center |
Compositions and methods for treating neonatal biliary atresia
|
WO2016200627A1
(en)
|
2015-06-09 |
2016-12-15 |
Children's Hospital Medical Center |
Dosing algorithm for complement inhibitor
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
EP3313443B9
(de)
|
2015-06-25 |
2023-10-04 |
Immunomedics, Inc. |
Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
|
EP3313437A1
(de)
*
|
2015-06-26 |
2018-05-02 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung eines patienten in übereinstimmung mit einer impfung mit eculizumab oder einer eculizumab-variante
|
EP3316885B1
(de)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
WO2017035355A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
EP3340982B1
(de)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Verbindungen zur behandlung von immun- und entzündungserkrankungen
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
US20170073399A1
(en)
|
2015-09-11 |
2017-03-16 |
Alexion Pharmaceuticals, Inc. |
Recombinant glycosylated eculizumab and eculizumab variants
|
EP3349773A4
(de)
|
2015-09-14 |
2019-05-01 |
Cincinnati Children's Hospital Medical Center |
Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors
|
WO2017062649A1
(en)
|
2015-10-07 |
2017-04-13 |
Alexion Pharmaceuticals, Inc. |
A method for treating age-related macular degeneration in a patient
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
WO2017075325A1
(en)
|
2015-10-30 |
2017-05-04 |
Alexion Pharmaceuticals, Inc. |
A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
|
CN108472382A
(zh)
|
2015-10-30 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
EP3389692B1
(de)
|
2015-12-16 |
2020-03-04 |
RA Pharmaceuticals, Inc. |
Modulatoren der komplementaktivität
|
PE20181402A1
(es)
|
2015-12-18 |
2018-09-07 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
AU2017269839A1
(en)
|
2016-05-27 |
2018-11-22 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
EP3463460A1
(de)
|
2016-06-07 |
2019-04-10 |
Novartis AG |
Anti-c5-antikörper-dosierschema
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
AU2017283470B2
(en)
|
2016-06-14 |
2024-03-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-C5 antibodies and uses thereof
|
MX2018015030A
(es)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso.
|
EP3939591A1
(de)
|
2016-06-27 |
2022-01-19 |
Achillion Pharmaceuticals, Inc. |
Chinazolin- und indolverbindungen zur behandlung von medizinischen leiden
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
US11053308B2
(en)
|
2016-08-05 |
2021-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating IL-8-related diseases
|
US20190276524A1
(en)
|
2016-10-12 |
2019-09-12 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
EP3526248A4
(de)
|
2016-10-17 |
2020-07-08 |
Musc Foundation for Research Development |
Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
|
WO2018075758A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5 in a sample
|
WO2018075761A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
WO2018081400A1
(en)
|
2016-10-27 |
2018-05-03 |
Alexion Pharmaceuticals Inc. |
Assay for c5b-9 deposition in complement-associated disorders
|
BR112019011053A2
(pt)
|
2016-12-07 |
2019-10-15 |
Ra Pharmaceuticals Inc |
moduladores da atividade do complemento
|
KR102514175B1
(ko)
|
2017-01-31 |
2023-03-29 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
CA3053818A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
ES2933513T3
(es)
|
2017-03-01 |
2023-02-09 |
Achillion Pharmaceuticals Inc |
Compuestos macrocíclicos para el tratamiento de trastornos médicos
|
US11274146B2
(en)
|
2017-03-23 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Anti-C5a antibodies and uses thereof
|
WO2018183449A1
(en)
|
2017-03-31 |
2018-10-04 |
Alexion Pharmaceuticals, Inc. |
Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine
|
EP4272821A3
(de)
|
2017-04-03 |
2024-01-03 |
InflaRx GmbH |
Behandlung von entzündlichen erkrankungen mit inhibitoren von c5a-aktivität
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
EP3612561A1
(de)
|
2017-04-19 |
2020-02-26 |
Alexion Pharmaceuticals, Inc. |
Wirksamkeit eines anti-c5-antikörpers bei der prävention einer antikörpervermittelten abstossung bei sensibilisierten empfängern eines nierentransplantats
|
PL3612208T3
(pl)
*
|
2017-04-21 |
2023-07-24 |
Volution Immuno Pharmaceuticals Sa |
Coversin do leczenia autoimmunologicznych chorób pęcherzowych
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
WO2018217638A1
(en)
|
2017-05-22 |
2018-11-29 |
Alexion Pharmaceuticals Inc. |
Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
|
SI3658184T1
(sl)
|
2017-07-27 |
2024-01-31 |
Alexion Pharmaceuticals, Inc., |
Formulacije z visoko koncentracijo protiteles proti-C5
|
JP2020536097A
(ja)
|
2017-10-04 |
2020-12-10 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
膜性増殖性糸球体腎炎患者の処置のための抗c5抗体の投薬量および投与
|
KR20200070355A
(ko)
|
2017-10-26 |
2020-06-17 |
알렉시온 파마슈티칼스, 인코포레이티드 |
발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
|
EP3704252A1
(de)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
CA3081801C
(en)
|
2017-11-29 |
2022-12-20 |
F. Hoffman-La Roche Ag |
Target interference suppressed anti-drug antibody assay
|
JP2021506241A
(ja)
|
2017-12-13 |
2021-02-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗c5抗体組み合わせ物およびその使用
|
CA3104295A1
(en)
*
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
KR20200033225A
(ko)
|
2018-08-01 |
2020-03-27 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
EP3841086A4
(de)
|
2018-08-20 |
2022-07-27 |
Achillion Pharmaceuticals, Inc. |
Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d
|
JP7443375B2
(ja)
|
2018-09-06 |
2024-03-05 |
アキリオン ファーマシューティカルズ, インコーポレーテッド |
医学的障害の治療のための大環状化合物
|
EP3847174A4
(de)
|
2018-09-06 |
2022-06-15 |
Achillion Pharmaceuticals, Inc. |
Morphische formen von komplementfaktor-d-inhibitoren
|
WO2020058759A1
(en)
|
2018-09-17 |
2020-03-26 |
Kyoto University |
Administration of an anti-c5 agent for treatment of hepatic injury or failure
|
US20200095307A1
(en)
|
2018-09-21 |
2020-03-26 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for the treatment of neuromyelitis optica
|
CA3114039A1
(en)
|
2018-09-25 |
2020-04-02 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
WO2020092546A1
(en)
|
2018-10-30 |
2020-05-07 |
Alexion Pharmaceuticals, Inc. |
Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
|
AU2019370295A1
(en)
|
2018-10-30 |
2021-06-03 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
WO2020106724A1
(en)
|
2018-11-20 |
2020-05-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
|
US20220017899A1
(en)
|
2018-11-23 |
2022-01-20 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of c3 in a cell
|
EP3730617A1
(de)
|
2019-04-26 |
2020-10-28 |
Silence Therapeutics GmbH |
Nukleinsäure zur hemmung der expression von c3 in einer zelle
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|
WO2020154626A1
(en)
|
2019-01-25 |
2020-07-30 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)
|
WO2020242849A1
(en)
|
2019-05-24 |
2020-12-03 |
Alexion Pharmaceuticals, Inc. |
Methods of treating vitiligo using an anti-c5 antibody
|
MX2022001154A
(es)
|
2019-07-31 |
2022-02-22 |
Hoffmann La Roche |
Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
|
WO2021019033A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
|
US20220259305A1
(en)
|
2019-08-05 |
2022-08-18 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis with eculizumab
|
BR112022003513A2
(pt)
|
2019-08-27 |
2022-05-17 |
Silence Therapeutics Gmbh |
Ácidos nucleicos para inibição da expressão de c3 em uma célula
|
CN115176004A
(zh)
|
2019-10-22 |
2022-10-11 |
阿尔尼拉姆医药品有限公司 |
补体成分C3 iRNA组合物及其使用方法
|
JP2023507852A
(ja)
|
2019-12-23 |
2023-02-27 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗c5抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
AU2020438234A1
(en)
|
2020-03-27 |
2022-09-29 |
Inflarx Gmbh |
Inhibitors of C5a for the treatment of corona virus infection
|
US20230416344A1
(en)
|
2020-04-16 |
2023-12-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating a complement mediated disorder caused by viruses
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
AU2021270867A1
(en)
|
2020-05-12 |
2022-12-08 |
Alexion Pharmaceuticals, Inc. |
Use of complement factor D inhibitors alone or in combination with anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
|
WO2021247908A1
(en)
|
2020-06-03 |
2021-12-09 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
AU2021294222A1
(en)
|
2020-06-16 |
2023-01-19 |
F. Hoffmann-La Roche Ag |
Method for determining the free antigen of an antibody in a sample
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下(sc)施用抗c5抗体治疗补体相关病症
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
CN115803058A
(zh)
*
|
2020-07-15 |
2023-03-14 |
博奥信生物技术(南京)有限公司 |
结合c5的抗体及其用途
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
KR20230147092A
(ko)
|
2021-01-22 |
2023-10-20 |
바이원큐어 테라퓨틱스, 인크. |
항-her-2/trop-2 작제물 및 이의 용도
|
EP4281472A1
(de)
|
2021-01-22 |
2023-11-29 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung von komplementvermittelter thrombotischer mikroangiopathie unter verwendung eines anti-c5-antikörpers
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
EP4348263A1
(de)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Verfahren zum nachweis von cm-tma-biomarkern
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
AU2022336157A1
(en)
|
2021-09-02 |
2024-03-14 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
|
US20230203176A1
(en)
|
2021-09-17 |
2023-06-29 |
Novartis Ag |
Methods For Prevention Of Graft Rejection In Xenotransplantation
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
CN116712390B
(zh)
*
|
2023-08-04 |
2023-11-14 |
上海览屹医药科技有限公司 |
一种高浓度高稳定性的抗体制剂及其制备方法
|